CTI Spin-Off Aims To Put Follow-On Biologics In The Clinic Within Two Years
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen products eyed as initial candidates, exec tells “The Pink Sheet” DAILY.
You may also be interested in...
CTI Plans To Spin Off Systems Medicine As Pharmacogenomics Company Apana
New firm’s management team is looking for pharma partners to validate its expertise, attract venture funding while parent CTI struggles to stay in business.
CTI Plans To Spin Off Systems Medicine As Pharmacogenomics Company Apana
New firm’s management team is looking for pharma partners to validate its expertise, attract venture funding while parent CTI struggles to stay in business.
Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon
Abraxis BioScience and Biocon have signed a licensing agreement that gives the Los Angeles firm the right to develop a biosimilar of granulocyte-colony stimulating factor in North America and the European Union, the companies announced July 19